<SEC-DOCUMENT>0001193125-16-737209.txt : 20161013
<SEC-HEADER>0001193125-16-737209.hdr.sgml : 20161013
<ACCEPTANCE-DATETIME>20161013081732
ACCESSION NUMBER:		0001193125-16-737209
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20161013
FILED AS OF DATE:		20161013
DATE AS OF CHANGE:		20161013

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		161934090

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d271824d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13A-16</FONT> OR
<FONT STYLE="white-space:nowrap">15D-16</FONT> UNDER THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated October&nbsp;13, 2016 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35428</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>RIMA</SMALL> B<SMALL>IO</SMALL>M<SMALL>ED</SMALL> L<SMALL>TD</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s Name) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by
check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;</FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;</FONT><FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (1):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;
&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): Not applicable. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: October&nbsp;13, 2016 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>Prima BioMed Ltd</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">PRIMA TO PRESENT AT 2016 SOCIETY FOR IMMUNOTHERAPY OF CANCER CONFERENCE</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d271824dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g271824g96g33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Media Release (Code: ASX: PRR; NASDAQ: PBMD) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13&nbsp;October 2016 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRIMA TO PRESENT AT 2016 SOCIETY FOR </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IMMUNOTHERAPY OF CANCER CONFERENCE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">SYDNEY, AUSTRALIA&#151;Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (&#147;Prima&#148;) announces that the submission titled &#147;LAG-3Ig (IMP321) in combination with anti-PD-1 therapy&#148; has been
accepted for a presentation at the Society for Immunotherapy of Cancer (SITC)&#146;s New Cancer Immunotherapy Agents in Development program. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This program, which is part of SITC 2016, is being held on Wednesday, November&nbsp;9, 2016 at the Gaylord National Hotel&nbsp;&amp; Convention Center in
National Harbor, Maryland. Dr Fr&eacute;d&eacute;ric Triebel, Prima&#146;s Chief Medical&nbsp;&amp; Scientific Officer, will deliver the presentation between 11:10am and 12:20pm. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About Prima BioMed </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prima BioMed is a globally active biotechnology company that is
striving to become a leader in the development of immunotherapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to
maximise value to shareholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prima&#146;s current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital
role in the regulation of the T cell immune response. IMP321, which is a soluble LAG-3Ig fusion protein, is an APC activator boosting T cell responses. IMP321 is currently in a Phase II clinical trial as a chemoimmunotherapy for metastatic breast
cancer termed AIPAC (clinicaltrials.gov identifier <U>NCT 02614833</U>) and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier <U>NCT 02676869</U>). A number of additional LAG-3 products
including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prima
BioMed is listed on the Australian Securities Exchange, and on the NASDAQ in the US. For further information please visit <U>www.primabiomed.com.au.</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>For further information, please contact: </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Australia Investor/Media: </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr Matthew Gregorowski, Citadel-MAGNUS </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">+61
(2)&nbsp;8234 0100; <U>mgregorowski@citadelmagnus.com</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>U.S. Investors: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Matthew Beck, The Trout Group LLC </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">+1 (646)&nbsp;378-2933; mbeck@troutgroup.com </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g271824g96g33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g271824g96g33.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=A8F4@3&%B
M;W)I;@    60 P "    %   $*:0!  "    %   $+J2D0 "     S<X  "2
MD@ "     S<X  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MVA33I_FAD#Y&X'T]Q7LU% #9 6C8#J017S?HG@WXE>#_ !GJFKZ!I$$ING<
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M:* /'[37/C&UY EUH5@L!D42,",A<\_I57XV>!_$GBCQ!HU]X>LA<?8TR^6
MPV[(KVJB@#P/6=+^,7C#3!I5Y!:Z;:, KF-PI8>YKT/X8?#>V^'NBO%YOVB]
MN<-<2XXSZ#VKN:* "BBBD 4444 %%%% 'RR"0<BI4N9X_N32+]&-(UM/']^"
M1?\ >0BF$8Z\5\YL?K&DD7(]9U*(YCOKA?I(:T[7QOXBM1B/5)B/1CFL"E%-
M3DMF82P]&?Q13^2.N7XE^)0/^/N,_6,5/!\4?$$;_OI(I%]/+ KBQ2U:K5/Y
MF8/ 826GLU]QZ5:_%ZY3'VJP63W5L5IP_%_3V \ZPG3Z$&O(Q2YK18JJNIR3
MR?!R^S;YL]HB^*VA/C>MPGUCS6E;?$#P]<@8OE3V<8KP:G"M%C:AS2R'#/9M
M'T1%XET>;_5ZC;G_ ('5I-3LI/\ 5W<+?205\W@XZ4]9'4Y#L/H:M8Y]4<LN
M'X?9G^!]+)(KC*L&'L:7-?.<.J7]O_J;R=/I(:T(?%FN18V:E-CW;-:+'1ZH
MYY9!47PS1[YFC->'1^//$$9_X_2P_P!I16A#\3-;CP'\F3ZK6BQM-G/+(\4M
MK,]AS2YKRF/XIZD/]9:0-^)%78?BLW'GZ:/JCU7UNEW,)91BX_9_$])HKB(?
MBAIK_P"NMIH_UJXGQ&T-^KRK]4JU7I/[1SRP&*CO!G5T5SL7CK09?^7O;_O*
M15Z'Q)I%Q_JK^$_5L5HJD'LS&6'K1^*+^XU**KIJ%H_W;F$_1Q4@N(F^[(A^
MC"JNF8N+6Z)**3<#T(I<TQ!111F@ HHHH ***,T %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4&BB@#Y@^,AU7QG\88/#5
MF&(B"QQ(>@)Y+5>^)?P.M/#_ (*AU700?/LHP;T,Q/F>K#TYKUK7?!2'Q]IW
MB_3TW7-N/+GB_P">B'N/<5L^+[6YU;PK=Z=81AIKZ(Q*7'RH#U)^E,#EO@5J
MUUJ_POM'O9#(\#M"K-UVCI7H]8/@SPK:^#O"]KI%F=RPK\[G^-CU-;U( HHH
MI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%%( HHHH ***,T 0R6=O*/WD$3?5 :S+OPEHE[GS].@)/<+BMFBI
M<4]T:1J3@[Q;1R$WPR\.2DD6SQY_N.16;<_"'29/^/:ZN(?Q#5Z#16;H4G]D
MZH9CBX;5']YY;/\ !PC_ (]]4S_OI63=_"G6H,_9Y(9Q['%>T4$5F\)2?0ZX
M9UC([RO\CP.;X?\ B.'/_$O9\?W&!K-N/#>L6F?M&G7"8[[,U]&T%0PPP!'O
M63P4.C.J'$%=?%%,^96@E0X>-U/NII ,=>*^DY-.LY?]9;0M]4%4I_#&C7'^
MLTZ _P# ,5D\"^C.J/$$'\4/Q/GJE%>W7'PW\/7!)%L\1_Z9N16?-\*-);/D
MW$\?U.:S>#JK8ZHYYA7O=?(\C%/%>D3_  D/_+OJ/_?:53E^%.I*#Y5W"_L<
MBLWAJJZ'1'-<'+[?YG"4M=-<?#WQ#;DXM!*/5'!JA+X6UN'_ %FG3C_@-9NG
M-;HZ8XK#SUC-?>98IPZ5/+IM[;_ZZUF3ZH:AP1P00?>L[-&JE&6S%%.!Q3!3
MZ!,<.M/6F#K3Q018>KL.C$?0U,ES,OW9I!]'-5UIXIW9+29>BU?4(3^[O9A_
MP,U?B\5ZS%]V]<_7FL04X=*M5)K9F$J-*3UBON.C3QMK:_\ +PI^JU:B\>ZP
MOWC$_P!4KE13Q5JM47VC"6#P[^PON.QC^(E\OW[6%OQ(JRGQ%E_CL5/T:N''
M6GBK6(J]S%Y?A7]@[V/XAQD_/9,![-5J+QY8-_K(94_#->=CI3UJUBJJZF,L
MKPW;\3TQ/&FDMU=U^JU.GBO2&_Y><?45Y>#3A5K%S,'E5#HV>IKXCTE^EY'^
M-6$U?3Y/N7<1_P"!5Y.*D'%7]<EV,GE-/I)GK2W=N_W9D/T84_SHST=3^->3
M*[#HQ'T-3+<S#I*X_P"!&K6+[HR>5=I?@>J;U/<4NX5Y>M[<#I/)_P!]&I4U
M.\7I<R?]]52Q2[&;RN?21Z9FBO.5US4$^[<O4R^)=37_ );Y^JU7UF/8C^RZ
MO1H] HS7!?\ "6:FO\:'ZI2_\)CJ(ZB(_P# :?UFF1_9M?R.\HS7"#QK?#K%
M$:>/'-T/O6T9^AI_6:?<G^SL1V_$[C-%<4/'C?Q6@_!J>/'R=[0_]]4?6:7<
M7]GXG^4[*BN.'Q A[VC_ /?5._X6!:#[UK(/Q%/ZQ2[D_4,3_(=?FBN27X@:
M>?O03"GCQ]I?\2S#_@-/V]+N)X+$K[#.JHKFE\=Z.>KR+]4J1?&VB-UN2/JM
M/VU-]2'A:Z^P_N.AHK"7QEHA_P"7U1]14@\6Z&?^8A$/K3]I#N3]6K?R/[C9
MHK('BO1#_P Q&'\Z7_A*=%_Z",/YT_:0[B]A5_E?W&M165_PD^C'_F(P_P#?
M5+_PDNC_ /00@_[ZHYX]Q>QJ_P K^XU**S/^$DT?_H(0?]]4?\)'H_\ T$(/
M^^Z?/'N'L:G\K^XTZ*S?^$BTC_H(0?\ ?='_  D6D?\ 00M_^^Q1S1[A[&I_
M*_N-*BLS_A(]'_Z"-O\ ]]B@^(]''74;?_OL4<T>X>QJ?RO[C3HK,_X231O^
M@C;_ /?=-_X2;1?^@E;_ /?='/'N'L:G\K^XU:*R3XHT0==2M_\ ONFGQ9H0
MZZG;_P#?5+GCW'["K_*_N-BBL4^,- '75(/^^J8?&GAX==4@_.CVD.X_J]9_
M8?W,W:*Y]O'/AQ1SJD/ZU"_Q!\-K_P Q!3] :7M:?=%?5<0]H/[F=-17(/\
M$OPXF<73M](S59_BKH*_=\]OHE3[:FOM%QP.*EM3?W'<45Y^_P 7-'7[MM<-
M^ %0-\8; ?=L)C]6%+ZQ2[FRRO&/_EVST>BO,G^,=O\ P:;(?J]02_&,X_=:
M9^;U+Q5+N6LHQK^Q^*/5,T5X[+\8=2/^JL8%^I)JM)\7-=;[L5LO_ <U+Q=)
M&L<CQKW27S/:Z3->&2_%+Q)(/EFA3Z1"L^X\?>)+@8?4G7V0 5+QM-;(WCP_
MBGNTCZ#+ =3BFM/$OWI$'U85\V3>(]8F.9-2N#_VT-57U.^D^_>3-]9#6;QR
MZ1.B/#M3[4U]Q])SZQIULI,][ @]Y!69/X[\-VY(?58"1V4YKYW>1Y/]8[-]
M3FFU'UV3V1U1X=I+XJC^X]ZG^*'AJ'[MR\O^XAK&O/C'IT;$6EC-+Z%CBO'J
M::SEC*CV.J&0X2/Q7?S/39_C/=$$6VF1K_ON35;_ (7'JW_/E;?F:\[HK+ZS
M5_F.I91@DOX:/JRBBBO=/S@**** "BBB@ HHHH **** "BBB@ HHHH *3%+1
M0!&\,<@_>1J_^\,U4ET339O];8P-]4%7Z*5D]RE*4=F8DWA#0IA\VFPCZ#%9
MUQ\.M$E),:21?[K5UE%0Z5-[HWCBZ\=IO[SA'^&%F3^ZO)5^H!JI-\+Y!G[/
M?@_[ZUZ-163PM)]#H69XM?;_ "/+)/AMJJ']W- _XXJK+X$UR+.+=7'^R^:]
M=HJ'@Z3V-XYQB5O9_(\2E\.ZM ?WEA-^"YJ!M.O(_OVLJ_5#7NG6F-&AZJI_
M"L_J4>YO'.ZGVHH\**,GWU9?J**]ODL+288EMHF^J"J4GAK2)?O6,6?88J'@
MI=&;1SJ#^*#/(!3Q7J<G@S1I/^7<K]&JE-X TU_]5)+'^.:CZG41M'-L.][H
M\[%/4\5VS_#Q1_J[YOHRU _P^NA_J[N-OJ#4/#U5T-5F.&E]HY(<T\5T#^"-
M4C^[Y;_1JA?PEJ\8_P"/?=]&J71J+[)HL50>TT9 IX.:MR:+J,/W[23\!FJY
MMKA#\\$B_534\K6Z+52$MF -/%1[''52/J*<#ZT#) :4-48-+FF*Q)FD)IN:
M3(HN%AQ---(32$XI (QIAH)III%+<0TPFE-,/%(L0TQCFG$TPGFD4AII&I33
M#298C4PFGTPTBD,---*:0FD4-IIYI33#2*$--/6G$YIA-!2$--XIQIAZ4%#3
M332TAHN4AIIO6G4W-!2$/TIII3TI#TH&--,IYIE!2#K2'BEIO6@H:329H-&*
M!B4E+BDH*$I#TI32'I0 VE[4E% T)1110,*0]:6D/6@I#310:* "BBB@04T]
M:4TE PHHHI ?5E%%%?2GY(%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2%%;[R@_44M%
M $36L#@[H8S_ ,!%59-%T^7[]K'^ J_12LBE.2V9C/X6TM_^7?'T-0OX/TUN
M@D7Z-6_14.E3?0V6)K+:3.6E\$VS?ZJXD7ZC-57\#2_\L[M3_O+79T5/L*;Z
M&JQV(7VCA7\$WO\ #-&:K2^#]33[JH_T:O0\45'U:F:K,L0NQYD_AC5E/-J3
M]#5>30M3C^]9R_@*]5Q1BH>$AW-8YM56Z1X]+8W47^LMY5^JFH&1UX9&'X5[
M.R*WWE!^HJ)K.V;[T$9^JBH>#\S>.</K#\3QE@?2HR:]E?2K!_O6D1_X"*K2
M^&M)E!W64?X"LW@Y=&;1SBGUBSR$FF$UZG+X(T:3.(73_=>JS_#_ $H_=>9?
M^!9J'@ZG0WCFV'>]SS,TTFO1I/AU9M_J[J5?J :IS?#=O^6-Z#_O+4/"U5T-
MHYIA7]K\#@C3#79R?#G4E/[N>%A[U7D^'NL#[ODM]&J'AZJZ'1''X5_;1R9I
MAKI)? NO1]+96_W7%4Y/">N1GYM.E_ 5G[*HNC-HXJA+::^\Q::>E:C^'M63
M[VGS#_@-5I-*OXQ\]I,OU0U/++L;1JTWM)?>4C334SV\R'YXG7ZJ:A8$>U39
MFR:>PVFFE-(:"T-S3#3C2&@H::0]*6FFD,::;3C3:90A-)2XIM QII3TI#24
M%"44&BD,0TA-+3:8"444&@:$HHHH&%(>M+2'K04AIHH-% !1110(0TE*:2@8
M4444@/JRBBBOI3\D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ Q1BBB@ HHHH ,48HHH 3%(8T/WE!^H
MIU% $+65L_W[>,_5!5=]%TV3[]C ?^V8J]12LF6IR6S,I_"^BR?>TVW/_ :K
MR>"_#\HYTV)?]W(K=HJ73@^A:Q%9;3?WLY6;X=>'Y>D#H?\ 9>J4OPMT=_N2
MSI_P+-=O14.A2?V3:..Q4=IL\_?X46/\%[,/J!5=_A+"1\FHN/JE>D48J?JU
M)]#99IC%]L\LF^$=Q_RQU!#_ +RU1E^%.L+_ *JXMW^I(KV&DQ4_5*78UCG.
M,7VK_(\5D^&'B)/NQP/]):K/\./$:_\ +HK?1Q7NF*,5#P=,V6>XI=%]W_!/
M Y/ 'B-!DZ<Q^A!JK)X0UZ+[VF3_ (+7T-1BI^I0[LU7$&(6\5^)\WMX>U=/
MO:;<?]\&H7T?44^]93C_ +9FOI7:/2D,:'JJ_E2^HQZ,U7$-3K!?>?,KV-VG
MWK68?5#4+0R)]^-Q]5-?3K6\3?>B0_514;:=9O\ ?M86^L8J7@?[QK'B+^:G
M^/\ P#YB^M!KZ4E\.Z1-_K-.MC_VS%5)/!7AZ7[VE6_X+4_49=)&JXBI=:;^
M\^=:*^A&\ >&V_YAD8^F:@?X;^&W_P"7+'T8U/U*IW-5Q!AOY7^!X$>E-KW:
M3X6^''Z0RK]'JI+\(M#?_5S7"?\  LU+P=7R-HY]A'O?[CQ0TE>P2?!JP/\
MJ]1G7ZJ#5=_@O'_!JSCZQBI^J5>QJL[P3^U^!Y/17J+_  7D_P"6>K+^,=0/
M\&;X?ZO4X#]4-+ZK5[&BSC!/[?X,\T-)7H<OP=U@?ZN[MG_,53E^$WB*/[H@
M?Z/4/#U?Y399G@W_ ,O$<11762?#/Q,G2R#?1Q4?_"N?$W_0//\ WT*GV-3^
+4T6/PK_Y>+[S_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
